Cargando…

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study

AIMS: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low‐density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miñana, Gema, Núñez, Julio, Bayés‐Genís, Antoni, Revuelta‐López, Elena, Ríos‐Navarro, César, Núñez, Eduardo, Chorro, Francisco J., López‐Lereu, Maria Pilar, Monmeneu, Jose Vicente, Lupón, Josep, Sanchis, Juan, Bodí, Vicent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083416/ https://www.ncbi.nlm.nih.gov/pubmed/31903686 http://dx.doi.org/10.1002/ehf2.12533

Ejemplares similares

Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study
por: Núñez, Julio, et al.
Publicado: (2016)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
por: Núñez, Julio, et al.
Publicado: (2017)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome
por: Núñez, Julio, et al.
Publicado: (2022)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure
por: Bertomeu‐Gonzalez, Vicente, et al.
Publicado: (2020)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction
por: Miñana, Gema, et al.
Publicado: (2022)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

Sex differences in mortality in stable patients undergoing vasodilator stress cardiovascular magnetic resonance
por: Miñana, Gema, et al.
Publicado: (2021)

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome
por: Gabaldon-Perez, Ana, et al.
Publicado: (2021)

Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial
por: del Canto, Irene, et al.
Publicado: (2022)

Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness
por: de la Espriella‐Juan, Rafael, et al.
Publicado: (2018)

A Novel Clinical and Stress Cardiac Magnetic Resonance (C-CMR-10) Score to Predict Long-Term All-Cause Mortality in Patients with Known or Suspected Chronic Coronary Syndrome
por: Marcos-Garces, Victor, et al.
Publicado: (2020)

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
por: Santas, Enrique, et al.
Publicado: (2020)

Sex‐Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum
por: Santas, Enrique, et al.
Publicado: (2021)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Magnetic resonance microscopy and correlative histopathology of the infarcted heart
por: Perez-Terol, Itziar, et al.
Publicado: (2019)

Prognostic Value of New‐Generation Troponins in ST‐Segment–Elevation Myocardial Infarction in the Modern Era: The RUTI‐STEMI Study
por: Cediel, Germán, et al.
Publicado: (2017)

Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
por: Miñana, Gema, et al.
Publicado: (2022)

Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion
por: Rios-Navarro, Cesar, et al.
Publicado: (2018)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Prognostic Value of the Interaction between Galectin-3 and Antigen Carbohydrate 125 in Acute Heart Failure
por: Núñez, Julio, et al.
Publicado: (2015)

Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study
por: de Gonzalo-Calvo, David, et al.
Publicado: (2018)

Microvascular Obstruction in ST-Segment Elevation Myocardial Infarction: Looking Back to Move Forward. Focus on CMR
por: Rios-Navarro, Cesar, et al.
Publicado: (2019)

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction
por: Amiguet, Martina, et al.
Publicado: (2023)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine
por: Miñana, Gema, et al.
Publicado: (2021)

Cardiac magnetic resonance outperforms echocardiography to predict subsequent implantable cardioverter defibrillator therapies in ST-segment elevation myocardial infarction patients
por: Marcos-Garcés, Víctor, et al.
Publicado: (2023)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Refractory congestive heart failure: when the solution is outside the heart
por: Pernias, Vicente, et al.
Publicado: (2019)

Homocysteine and long-term recurrent infarction following an acute coronary syndrome
por: Miñana, Gema, et al.
Publicado: (2021)

Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study
por: Revuelta‐López, Elena, et al.
Publicado: (2020)

Lung ultrasound and biomarkers in primary care: Partners for a better management of patients with heart failure?
por: Domingo, Mar, et al.
Publicado: (2020)

Can Natriuretic Peptides be Used to Guide Therapy?
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Destination Therapy with Left Ventricular Assist Devices in Non-transplant Centres: The Time is Right
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
por: de la Espriella, Rafael, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o2ipr9laf3fn2qem112cnanl67